"We plan to analyze these MRI structural measures longitudinally to determine if changes in brain volumes or lesion burden over time contribute to fatigue trajectories. More broadly, we might ...

Brain lesions — areas of brain tissue that show damage from injury or disease — are the biomarker most widely used to determine multiple sclerosis disease progression. But an innovative new study led ...

ZURICH (Reuters) - Actelion's experimental multiple sclerosis drug ponesimod met its main goal in a mid-stage trial, giving the Swiss biotech's pipeline a much-needed boost. Actelion has had a bumpy ...

Multiple sclerosis (MS) is the result of the immune system mistakenly attacking the brain and the spinal cord, causing tissue damage (lesions) throughout. While the underlying mechanism of lesion ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

Changes in NAWM and NAGM are crucial in MS progression, challenging the traditional lesion-centric model. Subtle alterations in myelin integrity, immune cell function, and neuronal connectivity ...

JUNEAU -- Rep. Charisse Millett said Monday that doctors have discovered a lesion in her brain that is most likely a sign she has multiple sclerosis. Millett, an Anchorage Republican who represents ...

ZURICH, August 2 (Reuters) - Swiss biotech company Actelion Ltd said on Tuesday a mid-stage study showed one of its drugs under development helped reduce new inflammatory brain lesions in a targeted ...